Do All People Lose Weight on Ozempic? Genetic & Biomarker Factors

Last reviewed: May 20, 2026

Last updated: May 20, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

No, not all people lose weight on Ozempic, despite its widespread clinical use. Clinical trials show average weight loss of 4–15% depending on dose and individual factors, but approximately 20–30% of users experience minimal or non-meaningful weight reduction.

Understanding why response varies is essential for treatment planning. Genetic predispositions in peptide signaling pathways, baseline metabolic biomarkers, and lifestyle adherence all influence whether a GLP-1 medication will produce clinically significant results for a specific patient.

The Clinical Reality of Variable GLP-1 Response

Clinical data from Ozempic and Wegovy trials demonstrate heterogeneous weight loss outcomes. Mean reductions range from 4% at lower doses to 15% at maximum doses, but individual results cluster around a wide distribution—some users achieve 20%+ loss while others see minimal change.

This variation is not random. Responders and non-responders differ in baseline insulin sensitivity, appetite-regulation neurobiology, gastrointestinal tolerance, and adherence patterns. Identifying these differences early can guide medication selection and dosing strategy.

Genetic Predispositions That Influence Peptide Signaling Response

Four key genetic variants in peptide regulatory pathways have been associated with differential GLP-1 and metabolic response. These are not deterministic—they represent predispositions that interact with environment, diet, and comorbidities. PlexusDx Precision Peptide Genetic Test evaluates these markers to help provide clinical context.

Genetic Variant	Gene	Associated Pathway	Clinical Relevance
rs6923761	GLP1R	GLP-1 receptor sensitivity	May influence appetite suppression magnitude and gastrointestinal tolerance
rs1800437	GIPR	Glucose-dependent insulinotropic peptide signaling	May affect insulin secretion response and metabolic efficiency
rs9939609	FTO	Energy homeostasis and appetite control	May predispose to greater appetite dysregulation and variable baseline satiety
rs17782313	MC4R	Melanocortin-4 pathway (central appetite)	May influence hypothalamic appetite signaling and weight set-point regulation

Biomarkers Associated with Better GLP-1 Treatment Response

The PlexusDx Precision Peptide Genetic Test analyzes GIPR, FTO, and MC4R — variants that relate to GLP-1 and related signaling pathways. It does not predict your response to Ozempic or determine your dose; it offers pathway-level context for a conversation with your provider. Genetics is a guide, not a guarantee.

Conversely, patients with normal fasting insulin, low triglycerides, and no insulin resistance may have smaller absolute weight losses because the medication's mechanism targets pathways already functioning adequately. This doesn't mean these patients shouldn't use GLP-1 therapy—it means providers should set realistic expectations and explore alternative or complementary approaches.

Why Some People Don't Lose Weight on GLP-1 Medications

Medication non-response can occur for several reasons: insufficient receptor sensitivity due to genetic variation, dose too low to reach therapeutic threshold, poor gastrointestinal tolerance limiting dose escalation, concurrent medications affecting metabolism, or inadequate behavioral adherence. Many cases reflect genuine physiological resistance rather than patient failure.

Providers should assess gastrointestinal tolerability, confirm adequate dosing, review for drug-drug interactions, and evaluate lifestyle factors (sleep, stress, physical activity) before concluding that GLP-1 therapy is ineffective. Switching to a different compound, adjusting formulation (oral vs. injection), or adding complementary agents may yield better outcomes.

Who Is Most Likely to Benefit: A Provider Decision Framework

Evidence suggests stronger weight loss in patients with baseline obesity class II–III (BMI >35), type 2 diabetes or prediabetes, insulin resistance markers, elevated inflammatory markers, and metabolic syndrome features. Age <65 and fewer comorbidities also correlate with better tolerance and adherence.

Patients with baseline normal weight, no metabolic dysfunction, or primary goal of modest cosmetic weight loss may benefit less dramatically and should understand realistic expectations. Genetic predisposition testing and biomarker assessment should inform individualized discussions about whether GLP-1 therapy is the optimal choice for that specific person.

How PlexusDx Supports a More Personalized Approach

PlexusDx Precision Peptide Genetic Test evaluates predispositions in four key variants (GIPR rs1800437, FTO rs9939609, MC4R rs17782313) within peptide signaling and appetite-regulation pathways. These results may help provide clinical context for why an individual's GLP-1 response might differ from population averages.

The genetic test reveals predispositions in how your body's peptide signaling systems are wired—not exact medication response. A variant in for example, may suggest lower baseline GLP-1 receptor sensitivity, which could inform dose titration strategy or indicate that a different medication class might be considered. Results should always be interpreted with your qualified healthcare provider.

Understanding your genetic predispositions in peptide pathways, combined with baseline biomarker assessment and clinical history, enables a more personalized conversation with your provider about which GLP-1 compound, formulation (oral vs. injection), and dosing schedule aligns with your physiology and goals. This precision-wellness approach moves beyond one-size-fits-all assumptions.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection is $289/mo month-to-month, or from $249/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $298 to personalize your protocol from day one.

Frequently Asked Questions

What share of users does the article say sees minimal weight reduction?

The post puts it at roughly 20-30% of users experiencing minimal or non-meaningful weight reduction, against average losses it describes as ranging from 4% at lower doses to 15% at maximum doses. It does not cite the source for either figure, so the numbers are best read as the article's framing of a wide distribution rather than as verified trial statistics.

Which explanations does the post give for non-response?

The article lists five: insufficient receptor sensitivity, a dose too low to reach the therapeutic threshold, poor gastrointestinal tolerance that prevents escalation, concurrent medications affecting metabolism, and inadequate behavioral adherence. It is careful to add that many cases reflect genuine physiological resistance rather than patient failure, which is the framing it uses throughout the piece.

What does the article say providers should rule out before calling the therapy ineffective?

The post says a provider should assess gastrointestinal tolerability, confirm the dose is adequate, review for drug-drug interactions, and evaluate lifestyle factors including sleep, stress, and physical activity. Only after that does it consider the therapy a failure. It suggests switching compounds, changing formulation between oral and injection, or adding complementary agents as next steps.

Which baseline profiles does the article link to stronger weight loss?

The post associates better outcomes with obesity class II to III at a BMI above 35, type 2 diabetes or prediabetes, insulin resistance markers, elevated inflammatory markers, and metabolic syndrome features. It adds that age under 65 and fewer comorbidities correlate with better tolerance and adherence. These are described as evidence-suggested patterns, not guarantees for any individual.

Why does the post say people with normal metabolic markers may lose less?

The article's reasoning is that the medication targets pathways that are already working properly in those patients. It says people with normal fasting insulin, low triglycerides, and no insulin resistance may see smaller absolute losses for that reason. It stops short of saying they should not use the therapy, arguing instead for realistic expectations and consideration of complementary approaches.

Related Reading

• What Are The Genetic Factors Affecting Ghrelin Production And Its Impact On Weight And Health
• Can Genetic Testing Help Me Lose Weight
• Ozempic For Losing Weight
• Ozempic For Weight Loss 2

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.